Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
A6NGE7

UPID:
URAD_HUMAN

ALTERNATIVE NAMES:
Parahox neighbor; Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase

ALTERNATIVE UPACC:
A6NGE7

BACKGROUND:
Putative 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase, also known as Parahox neighbor and Ureidoimidazoline decarboxylase, is essential for the stereoselective decarboxylation of OHCU to (S)-allantoin. This enzyme's activity is vital for understanding complex metabolic processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Putative 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase unveils new avenues for drug discovery. Its critical role in metabolism highlights its potential as a target for therapeutic intervention, promising advancements in medical treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.